Home > Healthcare > Medical Devices > Therapeutic Devices > Artificial Pancreas Device Systems (APDS) Market

Artificial Pancreas Device Systems (APDS) Market Trends

  • Report ID: GMI6912
  • Published Date: Oct 2023
  • Report Format: PDF

Artificial Pancreas Device Systems Market Trends

Rising demand for automated glycemic control systems such as APDS, technological advancements in CGM sensors, and increase in investment towards research and development by key players is driving the market progress. Technological improvements have transformed CGM sensors into smaller, more accurate, and less invasive devices, greatly enhancing patient comfort and overall usability. This heightened accuracy ensures that APDS can make precise insulin dosing adjustments, resulting in improved glycemic control and a reduced risk of hypoglycemia and hyperglycemia. As these technological advancements expand the appeal of APDS to a broader user base and gain increased clinical endorsement.
 

Traditional diabetes management methods involve multiple daily injections or manual adjustments of insulin doses, that can be burdensome and challenging for patients to maintain consistently. Thus, the demand for automated systems such as APDS is increasing among diabetic patients. Moreover, as demand increases, medical device companies are focusing on developing more advanced solutions, which can be another factor in the high adoption of APDS. For instance, the Medtronic MiniMed 780G artificial pancreas system has received approval from the Food and Drug Administration (FDA) for use in individuals aged 7 and above. This system offers automatic adjustments and real-time corrections to blood sugar levels at 5-minute intervals, including correction doses, as part of its meal detection technology.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global artificial pancreas device systems industry was valued at USD 331 million in 2022 and is estimated to account for USD 757.5 million by 2032.

The threshold suspends device systems segment garnered USD 175 million in 2022 and will grow through 2032 attributed to the advanced safety features of these devices.

U.S. artificial pancreas device systems industry accounted for USD 122 million in 2022 and is predicted to witness substantial growth through 2032 due to the surge in the diabetes population base in the country.

Medtronic Plc, Johnson & Johnson Services Inc., Bigfoot Biomedical, Tandem Diabetes Care, Inc., Pancreum, Inc., TypeZero Technologies, LLC, Beta Bionics, Insulet Corporation, Defymed, Inreda Diabetic, and Diabeloop.

Artificial Pancreas Device Systems Market Scope

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 11
  • Tables & Figures: 218
  • Countries covered: 22
  • Pages: 175
 Download Free Sample